The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

Circular Genomics recently moved its headquarters to Lilly Gateway Labs, aiming to enhance its Alzheimer's disease ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly revealed major advancements in its alopecia and atopic dermatitis studies, likely driving its 3.77% stock rise. The ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. Ricks' payout included $19.7 million in ...

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...